Cpi-613
Pancreatic Cancer Stage IV
Cornerstone PharmaceuticalsPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Pancreatic Cancer Stage IV cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Thalidomide Fudan University | Phase 3 | B |
cbp501 CanBas Co. Ltd. | Phase 2 | B |
Inno-206 University of Oxford | Phase 1 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →